Teresa Deangelis, MD
Neurology · New York, NYNPI 1164463808
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $74,126 of the $97,301 with a category attached, or 76.2%. Biogen accounts for 63.2% of it on its own, with 56 other manufacturers making up the rest. Reporting peaked in 2022 at $23,215 and has fallen 85.0% since, to $3,481 in 2025. Among neurology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 968 payments — averaging $100.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$61K
- AstraZeneca$14K
- Amgen$11K
- AbbVie$2K
- Novartis$2K
- EMD Serono, Inc.$886
- plus $6K from 51 others
Across 96 payments — averaging $2332.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Adamas Pharmaceuticals, Inc.$119K
- Novartis$56K
- Roche Products Limited$21K
- Biogen$20K
- EMD Serono, Inc.$9K
What the payments were for
- Consulting fees$6,0696%
- Speaking & faculty fees$74,12676%
- Travel & lodging$5521%
- Food & beverage$16,54517%
- Education$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,301 in reported general payments places this provider in the 90th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CopaxoneGlatiramer Acetate | 93 | $706,542 |
| SolirisEculizumab | 12 | $637,542 |
| TecfideraDimethyl Fumarate | 25 | $303,233 |
| Kesimpta PenOfatumumab | 29 | $301,939 |
| Avonex (4 Pack)Interferon Beta-1a | 20 | $222,761 |
| Dimethyl Fumarate | 111 | $203,830 |
| Glatiramer Acetate | 54 | $198,022 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 17 | $186,532 |
| RebifInterferon Beta-1a/Albumin | 14 | $148,670 |
| GlatopaGlatiramer Acetate | 36 | $136,036 |
| AubagioTeriflunomide | 13 | $119,547 |
| MayzentSiponimod | 11 | $106,164 |
| Dalfampridine ErDalfampridine | 72 | $92,427 |
| Nurtec OdtRimegepant Sulfate | 45 | $63,015 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Copaxone | $457 | $706,54293 claims |
| AstraZenecaSoliris | $13,658 | $637,54212 claims |
| BiogenTecfidera, Avonex (4 Pack) | $61,500 | $525,99445 claims |
| EMD Serono, Inc.Rebif | $886 | $148,67014 claims |
| SanofiAubagio | $240 | $119,54713 claims |
| NovartisMayzent | $2,034 | $106,16411 claims |
| PfizerNurtec Odt | $313 | $63,01545 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $148 | $16,41311 claims |
| Upsher-smith Laboratories LLCTopiramate | $17 | $30814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,623 neurology providers in New York.
Other neurology in New York
- Stephen KriegerNew York$1.1M
- Sheng-Han KuoNew York$657K
- Timothy VartanianNew York$468K
- Steven WolfNew York$428K
- David DodickNew York$426K
- David SimpsonNew York$403K
- Fred LublinNew York$383K
- Alexander ShtilbansNew York$374K
- Andrew LassmanNew York$359K
- Brian ApatoffNew York$295K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.